Skip to Content
You are currently on the new version of our website. Access the old version .
  • Indexed in
    Scopus
  • 24 days
    Submission to First Decision
  • 5 days
    Acceptance to Publication

Drugs and Drug Candidates

Drugs and Drug Candidates is an international, peer-reviewed, open access journal on drug discovery, development, and knowledge, published quarterly online by MDPI.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (215)

  • Review
  • Open Access

Phytochemical Composition and Colorectal Anticancer Activity of the Genus Solanum L.: An Updated Review

  • Pablo Vinícius Soares de Santana,
  • Heivila Monique da Silva Alexandre and
  • Juan Carlos Ramos Gonçalves
  • + 3 authors

Research on the genus Solanum L. has expanded significantly due to its potential as a source of bioactive secondary metabolites for oncological applications. Colorectal cancer (CRC) remains a major global health challenge, and traditional chemotherapy is often limited by severe side effects and resistance mechanisms. This review synthesizes current scientific literature regarding the phytochemical composition and in vitro colorectal anticancer activity of plants belonging to the genus Solanum L. The available studies encompass diverse experimental approaches, including crude extracts, bioactive fractions, isolated compounds, synergistic combinations, and novel nanoparticle delivery systems. Phytochemical analyses highlight alkaloids, glycoalkaloids, and phenolic compounds as the primary bioactive constituents responsible for suppressing CRC cell viability and inducing cytotoxic effects. Emerging strategies, such as green-synthesized nanoparticles and synergistic formulations with established or natural agents, represent promising avenues to enhance therapeutic efficacy and lower toxicity. Overall, Solanum L. species harbor a broad array of promising candidate molecules that warrant further mechanistic and in vivo investigation for CRC drug discovery.

Drugs Drug Candidates

1 November 2026

Herbarium specimens representing eleven species of Solanum L. (A) S. nigrum (K001871184); (B) S. elaeagnifolium (K001336352); (C) S. lycopersicum (K000265997); (D) S. tuberosum (K000914631); (E) S. lyratum (K000788319); (F) S. incanum (S25-6841); (G) S. xanthocarpum (LY0455320); (H) S. lycocarpum (S09-23099); (I) S. septemlobum (S09-35301); (J) S. sessiliflorum (K001897638); and (K) S. quitoense (K001058542). Image credits: Royal Botanic Gardens, Kew (A–E,J,K); Mia Ehn (F), Daniel Andersson (H), and Åsa Dalsätt (I), Swedish Museum of Natural History; and Picture (G), specimen held at the Université Claude Bernard Lyon 1 herbarium, with rights held by RECOLNAT (ANR-11-INBS-0004). All photographs are licensed under Creative Commons Attribution 4.0 International. Images were cropped, resized, and arranged within circular panels.
  • Article
  • Open Access

Deciphering Emodin as an Antimalarial Lead Through Integrated Molecular Modeling and Experimental Validation

  • Moyosoluwa Precious Oyewole,
  • Ikponmwosa Owen Evbuomwan and
  • Oluyomi Stephen Adeyemi
  • + 6 authors

Background: Malaria remains a major global health burden, further exacerbated by the rapid emergence of Plasmodium strains resistant to frontline antimalarial therapies. This has necessitated the search for alternative sources of therapy. Methods: Here, we demonstrated the antiplasmodial potential of emodin through an integrated computational and experimental approach. Emodin was retrieved from the PubChem database and subjected to molecular docking against key P. falciparum regulatory and metabolic enzymes PfCDPK1, PfCDPK2, PfCDPK4, PfHK, and PfLDH. Results: Emodin demonstrated strong predicted binding affinities, with docking scores of −8.061, −8.017, and −5.021 kcal/mol against PfCDPK2, PfCDPK4, and PfHK, respectively—values surpassing those of established reference inhibitors. ADME and toxicity profiling further supported the drug-like physicochemical properties and acceptable safety margins of emodin. In vivo evaluation using P. berghei-infected mice revealed that emodin reduced parasitemia by up to 85.9% and significantly restored hematological and oxidative stress parameters, including PCV, GSH, total protein, and MDA levels. Conclusions: Collectively, these findings support emodin as a computationally predicted antiplasmodial scaffold with a proposed mechanism that remains hypothetical pending biochemical and cell-based validation. Its favorable predicted pharmacological profile and in vivo efficacy underscore its promise for further preclinical optimization.

Drugs Drug Candidates

20 October 2026

  • Article
  • Open Access

Background/Objectives: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by β-amyloid (Aβ) and Tau protein accumulation, leading to neuroinflammation, oxidative stress, and neuronal death. Currently, no effective treatment is available. This study evaluated secretions from marine invertebrates Echinometra lucunter (EL), Zoanthus sociatus (ZS), Exaiptasia diaphana (ED), Palythoa caribaeorum (PC), Tubastraea tagusensis (TT) and Eudendrium carneum (EC) for potential neuroprotective, anti-inflammatory, and antioxidant effects in cellular models of AD. Methods: Cytotoxicity was assessed by MTT and fluorescence assays. IL-6 release was measured using a cytometric bead array, while reactive oxygen species (ROS) production was evaluated by DCFH-DA labeling followed by flow cytometry. Antioxidant capacity was assessed using DPPH and ABTS. Results: ED, EC, EL, PC, and ZS secretions reversed Aβ-induced cytotoxicity, while EC and ZS were protective in cocultures. ED, EL, PC, and TT reduced IL-6 release, and ZS lowered ROS production. TT and ZS enhanced antioxidant activity in treated groups, while ED, PC, and ZS showed antioxidant potential by the DPPH assay. Conclusions: The findings suggest anti-inflammatory and neuroprotective properties of the evaluated marine invertebrates’ secretions, with ZS likely exerting its effects through antioxidant mechanisms. These results contribute to the search for novel therapeutic strategies for AD.

Drugs Drug Candidates

19 October 2026

  • Brief Report
  • Open Access

Background/Objectives: Management of joint infections is evolving from using intravenous antimicrobials to oral therapies. Optimal treatment requires awareness of antimicrobial resistance patterns. This study aimed to produce a cumulative antimicrobial susceptibility testing report to help select oral antimicrobials in joint infections. Methods: An analysis encompassing the years 2020–2024 was performed using joint fluid data from LifeLabs British Columbia regional laboratories connected with 129 community patient service centres. Results: A total of 275 out of 3525 joint fluid specimens showed microorganism growth, with the most common being methicillin-resistant Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus, and staphylococci other than Staphylococcus aureus. When these microorganism isolates were analyzed together, the tetracycline and sulfamethoxazole-trimethoprim sensitivities each failed to show significant difference from each intravenous therapy’s (cefazolin, cloxacillin, or vancomycin) sensitivity (p > 0.05). Clindamycin showed significantly lower sensitivity than vancomycin, while erythromycin showed significantly lower sensitivity than each intravenous therapy (p < 0.05). Conclusions: These findings require further verifications with prospective clinical trials that examine the clinical efficacy of different therapies. Careful consideration of therapeutic choices by clinicians is warranted to maximize treatment success.

Drugs Drug Candidates

28 September 2026

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Drugs Drug Candidates - ISSN 2813-2998